Holen Sie sich die Stockscreener-App
3.10
0.32%
-0.010
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - MarketScreener
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire
Lipocine’s Partner Files New Drug Submission in Canada - TipRanks
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan
Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World
Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks
Q2 Earnings Forecast for Lipocine Issued By HC Wainwright - Defense World
HC Wainwright Upgrades Lipocine (NASDAQ:LPCN) to Strong-Buy - Defense World
Lipocine’s (LPCN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Lipocine (LPCN) Receives Buy Rating from HC Wainwright & Co. | L - GuruFocus
Lipocine (LPCN) Gains Analyst Confidence with Buy Rating and Fut - GuruFocus
Lipocine Gains Bullish New Coverage, With Stock (LPCN) Down 30% YTD - AskTraders.com
Lipocine (LPCN) Gains Analyst Confidence with Buy Rating and Future Prospects | LPCN Stock News - GuruFocus
Lipocine (NASDAQ:LPCN) Share Price Crosses Above Fifty Day Moving Average – Here’s Why - Defense World
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - Nasdaq
Lipocine’s LPCN 1148 Gains Fast Track Designation - TipRanks
Lipocine (NASDAQ:LPCN) Share Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - Longview News-Journal
Lipocine to Present at A.G.P. Healthcare Showcase - TipRanks
Lipocine Reveals Next-Gen Oral Drug Delivery Platform at Major Healthcare ConferenceKey Developments Expected - Stock Titan
Lipocine Updates Corporate Presentation for Stakeholders - TipRanks
Lipocine To Present At H.C. Wainwright Annual Neuropsychiatry Virtual Conference - Barchart.com
Lipocine: Q1 Earnings Snapshot - CT Insider
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 30, 2025 - marketscreener.com
Lipocine Reports Q1 2025 Financial Results - TipRanks
Lipocine Inc. SEC 10-Q Report - TradingView
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - Morningstar
Renaissance Technologies LLC Sells 4,300 Shares of Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine announces license and supply agreement with Ache - TipRanks
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - Eagle-Tribune
Lipocine Partners with Aché for TLANDO® in Brazil - TipRanks
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock Ne - GuruFocus
Lipocine partners with Aché to market TLANDO in Brazil By Investing.com - Investing.com Canada
Lipocine partners with Aché to market TLANDO in Brazil - Investing.com
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock News - GuruFocus
Lipocine Targets Booming Brazil Testosterone Market with Exclusive TLANDO License Deal as Growth Hits 34% - Stock Titan
Lipocine Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Boosts Holdings in Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):